The routinely available oral medicines interfere with replication of the virus, but this treatment is designed to allow the immune system to respond more effectively to the virus and
subsequently reduce the frequency of recurrences and
reduce viral shedding. This phase 1 study is being conducted at several sites in the US. For more information contact Jessica Rowlands at Feinstein Kean Healthcare, 202-729-4089.
The next research study is sponsored by AiCuris, a German company.